Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel in High-risk Pediatric and Young Adult B-ALL (CASSIOPEIA)
NCT03876769Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Oct 2027
- Countries
- 11
01
Overview
A Phase 2 trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Novartis. Started Jun 2019; status: active, not recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03876769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876769.